A Phase 1 Clinical Trial to Evaluate Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib

Trial Profile

A Phase 1 Clinical Trial to Evaluate Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 24 May 2016 Planned End Date changed from 1 Feb 2018 to 1 Nov 2018.
    • 24 May 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top